RESUMO
PIP: The effects of lynestrenol, administered continuously in the dose of .5 mg/day, were studied in 50 women during 1146 menstrual cycles. 45 patients completed 24 cycles each. Before treatment and every 6 cycles all patients were subjected to questioning, physical examination, cytological, blood and urea nitrogen tests and urinalysis. 50% were also subjected to hepatic function tests (sulfobromophtalein excretion, glutamic oxalacetic transaminase, alkaline phosphatase, cephalin-cholesterol flocculation) and endometrial biopsies every 6 cycles. Subjective side effects were absent and weight and blood pressure remained unchanged. Laboratory tests and cytological studies showed normal results. Only 14% of the biopsies performed showed interferen ce with the normal hormonal transformation of the endometrium. The average duration of menstruation was 4-5 days; 7% of all cycles were shortened by 5-10 days and .2% by 11-14 days. 7% of the cycles were prolonged by 5-10 days and .8% by 11-20 days. Amenorrhea was present in .4% of the cycles. Irregular bleeding (either spotting or breakthrough bleeding) was present in 14% of the cycles. 6 patients (12%) stopped the treatment for this reason. It is concluded that the preparation studied is effective and very well tolerated. Patients must be advised regarding the possibility of irregularities in the menstrual cycle, the efficacy of the drug and the absence of other unwanted side effects, to decrease the dropout rate.^ieng
Assuntos
Linestrenol/farmacologia , Menstruação/efeitos dos fármacos , Adolescente , Adulto , Ensaios Clínicos como Assunto , Anticoncepcionais Orais Sintéticos/farmacologia , Avaliação de Medicamentos , Feminino , Humanos , GravidezAssuntos
Mama/efeitos dos fármacos , Anticoncepcionais Orais Sintéticos/farmacologia , Anticoncepcionais Orais/farmacologia , Adulto , Fatores Etários , Biópsia , Mama/patologia , Muco do Colo Uterino/efeitos dos fármacos , Endométrio/efeitos dos fármacos , Etinilestradiol/farmacologia , Feminino , Humanos , Linestrenol/farmacologia , Noretindrona/farmacologia , Norgestrel/farmacologia , Fatores de TempoRESUMO
PIP: Experience with the oral contraceptive Ovostat (.1 mg mestranol and 1 mg lynestrenol) in 324 women (5714 cycles) is reported. Only 1 pregnancy was observed, in a patient who had forgotten several pills. Side effects included headache (11 patients), nervousness (5 patients), amenorrhea (4 patients), and chloasma (3 patients). Breakthrough bleeding and spotting were rare. Cervical mucus (samples on Days 9-11 and 13-15 in 50 women) was uniformly inhospitable to sperm: low viscosity, negative Farn test, constant pH. Endometrial biopsy showed tissue typical of "suppressed" endometrium.^ieng
Assuntos
Anticoncepcionais Orais/administração & dosagem , Linestrenol/administração & dosagem , Mestranol/administração & dosagem , Adulto , Muco do Colo Uterino/efeitos dos fármacos , Ensaios Clínicos como Assunto , Anticoncepcionais Orais/efeitos adversos , Tolerância a Medicamentos , Endométrio/efeitos dos fármacos , Feminino , Humanos , Linestrenol/efeitos adversos , Linestrenol/farmacologia , Mestranol/efeitos adversos , Mestranol/farmacologia , México , Hemorragia Uterina/induzido quimicamenteRESUMO
PIP: 100 healthy fertile women, with active sexual lives and of reproductive age, were treated during 10 cycles in 1 year with mestranol-lynestrenol of the sequential type, for the purpose of determining the effectiveness of the drug as a contraceptive and study its effects on endometrial morphology, endocervical mucus, cervicovaginal cytology and urinary excretion of pregnanediol. The changes in the menstrual cycle and side effects were observed. The results obtained clearly show that the combination of mestranol-lynestrenol is an effective contraceptive (no pregnancy occurred), safe and well tolerated, with minimal side effects.^ieng